

leadership team. On bioRxiv, this is usually completed in 48 hours. On medRxiv, papers are scrutinized more closely because they may be more directly relevant to health, so the turnaround time is typically four to five days.

Sever emphasizes that the vetting process is mainly used to identify articles that might cause harm – for example, those claiming that vaccines cause autism or that smoking does not cause cancer – rather than to evaluate quality. For medical research, this also includes flagging papers that might contradict widely accepted public-health advice or inappropriately use causal language in reporting on a medical treatment.

But during the pandemic, screeners are watching for other types of content that need extra scrutiny – including papers that might fuel conspiracy theories. This extra screening

**“There was perhaps a misconception that there are no screening checks that go on with preprint servers.”**

was put in place at bioRxiv and medRxiv after a backlash against a now-withdrawn bioRxiv preprint that reported similarities between HIV and the new coronavirus, which scientists immediately criticized as poorly conducted science that would prop up a false narrative about the origin of SARS-CoV-2. “Normally, you don’t think of conspiracy theories as something that you should worry about,” Sever says.

These heightened checks and the sheer volume of submissions have meant that the servers have had to draft in more people. But even with the extra help, most bioRxiv and medRxiv staff have been working seven-day weeks, according to Sever. “The reality is that everybody’s working all the time.”

### Growing trend

ArXiv and ChemRxiv, a preprint server for chemistry, have also seen their share of COVID-19 papers. ArXiv has posted more than 800 and ChemRxiv has around 200. Both platforms have enhanced their screening procedures for COVID-19-related papers, although neither has stopped posting all studies with treatment-related computational predictions. “If all the [preprint platforms] had the same standards, then we’d be systematically shutting out the same voices,” says Steinn Sigurdsson, arXiv’s scientific director. “We want to have somewhat overlapping domains.”

Marshall Brennan, ChemRxiv’s publishing manager, says that when it comes to papers about treatments, they are “taking much more liberty than we normally would to send those back to the authors to say, ‘Look, this science here is suitable for a preprint server, but you can’t make these claims in the context

of a public-health crisis.” He notes that, in one such paper, the authors had recommended a home remedy for COVID-19 entirely on the basis of a computational analysis. That paper was swiftly rejected.

### Expedited publication

The abundance of coronavirus research is also reshaping peer review at journals. Several titles, including *Science*, journals published by Cell Press, *The BMJ* and *Nature*, report a surge in coronavirus-related submissions, and many have accelerated the peer-review process to ensure rapid dissemination.

A preprint posted in April on bioRxiv2 found that many medical-research journals had drastically speeded up publication pipelines for COVID-19 papers (S. P. J. M. Horbach. Preprint at bioRxiv <http://doi.org/dt3r;2020>). The analysis, which included 14 journals, found that average turnaround times had fallen from 117 to 60 days (see ‘Pandemic publishing’). (The study omitted several influential journals, such as *JAMA*, *The Lancet* and *The New England Journal of Medicine* because of a lack of appropriate data.) Some journals went from submission to publication in two weeks or less.

“That really makes one wonder how thorough this process really is,” says the study’s author, Serge Horbach, a doctoral student at Radboud University in Nijmegen, the Netherlands.

Howard Bauchner, the editor-in-chief of *JAMA*, notes that low-quality submissions are rising. Journals in the JAMA Network have received 53% more submissions in the first quarter of this year than in the same period in 2019. “Many of these are related to COVID-19, but most are of low quality,” Bauchner says.

To address the need for rapid review, a group of publishers and scholarly-communication organizations announced an initiative last month to accelerate the publication of COVID-19 papers using measures such as asking people with relevant expertise to join a list of rapid reviewers. The initiative’s members include Outbreak Science Rapid PREview, a platform where researchers can request or provide swift reviews of outbreak-related preprints.

Even in the light of expedited publication, it is important to remember that “the role of the journal is to say: ‘This has been fairly peer-reviewed, statistically reviewed, and can be relied on,’ rather than, ‘This is coming out at you as fast as it possibly can,’” says Theodora Bloom, executive editor of *The BMJ* and a co-founder of medRxiv. Still, Bloom notes that the COVID-19 papers submitted to her journal “are being handled at the fastest rate possible.”

Unlike preprint servers, being published in a journal gives papers the appearance of being reliable and valid knowledge, Horbach adds. “Nonsense or incorrect science in one of these papers is potentially much more harmful.”

Q&amp;A

## Pandemic economics



**Economists are striving to make sense of the coronavirus pandemic’s dramatic effects on the economy. Arthur Turrell, a physicist-turned-researcher at the Bank of England, spoke to *Nature* about tracking the real-time and long-term financial impacts.**

### Has the pandemic changed your work?

It’s changed my focus. It’s boosted one of our efforts to provide better monitoring of the current economic situation for the bank’s policymakers. Typical macroeconomic data points, such as those on gross domestic product, come out quarterly. Now changes are happening weekly. And with policies such as lockdown, it’s like whole sectors of the economy have been turned off. So we’ve had to think differently. We’ve been using tools from data science and computer science to automatically collect and analyse data when they come out, and to create a report for policymakers.

### What kind of research are you doing?

It’s important to understand the interaction between the macroeconomy and the progression of the disease. One project I’m working on is melding macroeconomic and epidemiological models. We slammed together two simple macroeconomic and epidemiological models. ‘Compartmental models’ in epidemiology study the dynamics of infectious diseases by dividing the population into groups, such as people who are infectious or recovered. It’s not that familiar to economists, but might be better known to those of us with science backgrounds. We’ve made most progress on that type of model for combining macroeconomics and epidemiology.

### What can these models tell you?

For instance, perhaps people who have long-term health effects from the virus won’t go to work in the same way as before, or people will keep working from home. Those are economic impacts of the virus.

### Interview by Elizabeth Gibney

This interview has been edited for length and clarity.